Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satoreotide tetraxetan in neuroendocrine tumors
NCT02592707Phase 2Terminated
- Sponsor
- Ipsen
- Start
- Mar 2017
- Primary completion
- Feb 2022
- Modality
- Peptide-Drug Conjugates
- Countries
- 8
01
Overview
A Phase 2 trial of satoreotide tetraxetan in neuroendocrine tumors (NETs), sponsored by Ipsen. Started Mar 2017; status: terminated.
02
Drugs
satoreotide tetraxetan
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT02592707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02592707.